Products
Platform
Research
Market
Learn
Partner
Support
IPO

B

Balaxi Pharmaceuticals Share Price

23.71
-1.01 (-4.09%)
BALAXI • 20 Jan, 2026 | 03:29 PM

1Y Annualised Return

-66.51%

3Y Annualised Return

-39.93%

5Y Annualised Return

-28.03%

10Y Annualised Return

19.39%

The current prices are delayed, login or Open Demat Account for live prices.

Balaxi Pharmaceuticals Stock Performance

1W Return-8.17
1Y Return-68.14
Today's Low23.4
Prev. Close24.72
Mkt Cap (Cr.)136.47
1M Return-14.80
3Y Return-79.29
52-Week High76.28
Open24.06
PE Ratio33.86
6M Return-51.62
Today's High25
52-Week Low23.4
Face Value2

Balaxi Pharmaceuticals Company background

Founded in: 1942
Managing director: Ashish Maheshwari
Balaxi Ventures Limited was formerly incorporated in the name of The Anandam Rubber Company Limited on September 28, 1942. The Company changed its name from The Anandam Rubber Company Limited to Balaxi Ventures Limited on August 08, 2017. The Company incorporated with a basic objective of running rubber and tea plantations and owns several plantations across South India. In year 1989 the company sold its entire plantations to meet the emerging business needs and started concentrating in Investments and trading. The company previously was a investment company, but the company during the financial year 201819 has commenced the business of International Wholesale Trading of Pharmaceuticals, Builders Hardware and FMCG Products On 15 March 2017, Balaxi Overseas Private Limited (BOPL) entered into a Share Purchase Agreement (SPA) with the erstwhile promoters of Company (i.e. Mr. Nirej V. Paul, Mr. V. M. Paulose, Dr. Leelamma T. J and Mrs. Jaya Paul) to acquire 1,670,036 Equity Shares representing 54.94% of the paid up share capital of the Company along with the control over the Company, pursuant to which BOPL made an Open Offer under Regulation 3(1) and Regulation 4 of SEBI (SAST) Regulations, 2011. Control and management of the Company was acquired by BOPL on May 04, 2017 and it became the new promoter of Company and their representatives i.e. Mr. Ashish Maheshwari and Mrs. Minoshi Maheshwari became the new Directors of the Company. Simultaneously, erstwhile promoters stepped down as promoters from Company on same day and Mr. Nirej V. Paul and Dr. Leelamma TJ resigned as Managing Director and as Chairperson from the Company, respectively. Under the above said Open Offer, BOPL acquired 3,30,000 equity shares representing 10.86% equity share capital of the Company. On completion of the Open Offer BOPL became the holding and Promoter Company with an aggregate shareholding of 2000036 Equity Shares (ie 65.79%).The main objects of the company were amended to include activities of International wholesale trading in pharmaceutical, food products and builders hardware on August 08, 2018. The Company commenced the business of International Wholesale Trading of Pharmaceuticals, Builders Hardware and FMCG products from Financial Year 201819.Further, in February 2019, it kickstarted Food Products business by launching a range of biscuits under the brand YAP.The Company expanded its presence by establishing a central distribution warehouse in Guatemala, marking its entry into the third geography. This expansion helped in strengthening the distribution network and a wider customer base in 2019. In FY 2023, Company started operations in two Latin American Countries, i.e., Honduras and El Salvador and also started operations inthe Central African Republic.

Balaxi Pharmaceuticals Financial Highlights


For the full year FY2025–2026, revenue reached ₹288.84 crore and profit touched at ₹25.07 crore.

Balaxi Pharmaceuticals Share Price Today


As of 20 Jan 2026, Balaxi Pharmaceuticals share price is ₹23.7. The stock opened at ₹24.1 and had closed at ₹24.7 the previous day. During today’s trading session, Balaxi Pharmaceuticals share price moved between ₹23.40 and ₹25.00, with an average price for the day of ₹24.20. Over the last 52 weeks, the stock has recorded a low of ₹23.40 and a high of ₹76.28. In terms of performance, Balaxi Pharmaceuticals share price has declined by 51.6% over the past six months and has declined by 66.51% over the last year.
Read More
Balaxi Pharmaceuticals SIP Return Calculator
5,000
Over the past
Total Investment of ₹0
Monthly SIP of 5,000 would have become 0 in 5 years with a gain of 0 (+0.00%)
View details of Market Depth

Balaxi Pharmaceuticals Fundamental

Market Cap (in crs)

136.47

Face Value

2

Turnover (in lacs)

9.16

Key Metrics

Qtr Change %
New 52W Low today
-42.3
Dividend yield 1yr %
0

Balaxi Pharmaceuticals Key Financials

View more
Loading chart...
Balaxi Pharmaceuticals Quarterly Revenue
Balaxi Pharmaceuticals Yearly Revenue
Balaxi Pharmaceuticals Quarterly Net Profit/Loss
Balaxi Pharmaceuticals Yearly Net Profit/Loss

Balaxi Pharmaceuticals Result Highlights

  • Balaxi Pharmaceuticals Ltd reported a 16.3% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 21.2%.

  • Its expenses for the quarter were down by 17.2% QoQ and 16.7% YoY.

  • The net profit decreased 27.6% QoQ and decreased 95.4% YoY.

  • The earnings per share (EPS) of Balaxi Pharmaceuticals Ltd stood at 0.04 during Q2 FY 2025-26.

    Read more

Data Source: BSE, Company announcements

The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

Balaxi Pharmaceuticals Shareholding Pattern

Promoter
66%
Foreign Institutions
1.7%
Domestic Institutions
0.1%
Public
32.2%

Balaxi Pharmaceuticals Technical Analysis

Moving Averages Analysis
23.71
Current Price
Bullish Moving Averages
0
Bearish Moving Averages
16
Day EMA5
25.30
Day EMA10
26.00
Day EMA12
26.20
Day EMA20
27.30
Day EMA26
28.10
Day EMA50
31.40
Day EMA100
36.80
Day EMA200
46.10
Delivery & Volume
Loading chart...

Day

66.90%

Week

62.40%

Month

65.00%

Delivery & Volume

24.69
Pivot
Resistance
First Resistance
25.01
Second Resistance
25.31
Third Resistance
25.63
Support
First Support
24.39
Second support
24.07
Third Support
23.77
Relative Strength Index
29.11
Money Flow Index
48.13
MACD
-1.93
MACD Signal
-2.02
Average True Range
1.66
Average Directional Index
20.88
Rate of Change (21)
-14.23
Rate of Change (125)
-49.46
Compare

Please be aware that Balaxi Pharmaceuticals stock prices are subject to continuous fluctuations due to various factors.

Open Demat Account